Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands

Acta Oncologica

Volumn 56, Issue 1, 2017, Pages 101-103

  van der Kooij, M K ^a   Joosse, A ^a   Speetjens, F M ^a   Hospers, G A P ^b   Bisschop, C ^b   de Groot, J W B ^c   Koornstra, R ^d   Blank, C U ^e   Kapiteijn, E ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c Isala ^*  (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

NIVOLUMAB; PEMBROLIZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; AGED; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL OUTCOME; FEMALE; HUMAN; LETTER; MALE; METASTATIC UVEA MELANOMA; MIDDLE AGED; NETHERLANDS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; CANCER STAGING; FOLLOW UP; IMMUNOLOGY; LYMPH NODE METASTASIS; MELANOMA; PROGNOSIS; SECONDARY; SURVIVAL RATE; UVEAL NEOPLASMS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; NETHERLANDS; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR; SURVIVAL RATE; UVEAL NEOPLASMS;

EID: 85001119083     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/0284186X.2016.1260773     Document Type: Letter

References (14)

1. Mallone S, De Vries E, Guzzo M, et al. Descriptive epidemiology of malignant mucosal and uveal melanomas and adnexal skin carcinomas in Europe. Eur J Cancer. 2012;48:1167–1175.
2. Hughes MS, Zager J, Faries M, et al. Results of a randomized controlled multicenter phase III trial of percutaneous hepatic perfusion compared with best available care for patients with melanoma liver metastases. Ann Surg Oncol. 2016;23:1309–1319.
3. Stinauer MA, Kavanagh BD, Schefter TE, et al. Stereotactic body radiation therapy for melanoma and renal cell carcinoma:impact of single fraction equivalent dose on local control. Radiat Oncol. 2011;6:34.
4. Shashank A, Shehata M, Morris DL, et al. Radiofrequency ablation in metastatic melanoma. J Surg Oncol. 2014;109:366–369.
5. Huppert PE, Fierlbeck G, Pereira P, et al. Transarterial chemoembolization of liver metastases in patients with uveal melanoma. Eur J Radiol. 2010;74:38–44.
6. Pawlik TM, Zorzi D, Abdalla EK, et al. Hepatic resection for metastatic melanoma:distinct patterns of recurrence and prognosis for ocular versus cutaneous disease. Ann Surg Oncol. 2006;13:712–720.
7. Carvajal RD, Sosman JA, Quevedo JF, et al. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma:a randomized clinical trial. JAMA. 2014;311:2397–2405.
8. Kivelä T, Suciu S, Hansson J, et al. Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma. Eur J Cancer. 2003;39:1115–1120.
9. Kelderman S, van der Kooij MK, van den Eertwegh AJM, et al. Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O). Acta Oncol. 2013;52:1786–1788.
10. Zimmer L, Vaubel J, Mohr P, et al. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naive patients with metastatic uveal melanoma. PLOS One. 2015;10:e0118564.
11. Maio M, Danielli R, Chiarion-Sileni V, et al. Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. Ann Oncol. 2013;24:2911–2915.
12. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours:revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–247.
13. Kottschade LA, McWilliams RR, Markovic SN, et al. The use of pembrolizumab for the treatment of metastatic uveal melanoma. Melanoma Res. 2016;26:300–303.
14. Algazi AP, Tsai KK, Shoushtari AN, et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer. 2016;122:3344–3353.